99-197
CALGB 9862:MOLECULAR GENETIC FEATURES OF ACUTE LYMPHOBLASTIC LEUKEMIA more details
Protocol
Consent Form
|
|
| |
99-022
CALGB 29801 MOLECULAR AND CYTOGENETIC MONITORING OF CML more details
Protocol
Consent Form
|
|
| |
94-138
CALGB 8461: CYTOGENETIC STUDIES IN ACUTE LEUKEMIA more details
Protocol
Consent Form
|
|
| |
96-242
THE CALGB LEUKEMIA TISSUE BANK more details
Protocol
Consent Form
|
|
| |
97-255
CALGB 9760: MULTIDRUG RESISTANCE STUDIES IN ACUTE LEUKEMIA more details
Protocol
Consent Form
|
|
| |
05-033
E2902: A PHASE III RANDOMIZED STUDY OF FARNESYL TRANSFERASE INHIBITOR R115777 IN AML PATIENTS IN SECOND OR SUBSEQUENT REMISSION OR IN REMISSION AFTER PRIMARY INDUCTION FAILURE OR PATIENTS OVER AGE 60 IN FIRST REMISSION more details
Protocol
Consent Form
|
|
| |
06-276
SWOG S9910: LEUKEMIA CENTRALIZED REFERENCE LABORATORIES AND TISSUE REPOSITORIES
more details
Protocol
Consent Form
|
|
| |
05-273
CALGB 20203: MOLECULAR MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA more details
Protocol
Consent Form
|
|
| |
06-286
PHASE III STUDY OF THE ADDITION OF GEMTUZUMAB OZOGAMICIN (MYLOTARG)DURING INDUCTION THERAPY VERSUS STANDARD INDUCTION FOLLOWED BY CONSOLIDATION AND RANDOMIZATION TO EITHER GEMTUZUMAB OZOGAMICIN OR NO THERAPY FOR PTS UNDER AGE 61 WITH UNTREATED AML more details
Protocol
Consent Form
|
|
| |
06-301
A PHASE 1/2 STUDY OF SKI-606 IN PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIAS more details
Protocol
Consent Form
|
|
| |
2007-311
A PHASE I DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF XL228 ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA-CHROMOSOME-POSTIVE ACUTE LYMPHOCYTIC LEUKEMIA (PH+ALL) more details
Protocol
Consent Form
|
|
| |
2007-353
Lenalidomide Following Rituximab and Fludarabine in Untreated Chronic Lymphocytic
Leukemia more details
Protocol
Consent Form
|
|
| |
2008-236
Phase I/II Study of Milatuzumab (hLL1) in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (CLL) more details
Protocol
Consent Form
|
|
| |
2008-141
CALGB 10403:An Intergroup Phase II Clinacal Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia. more details
Protocol
Consent Form
|
|
| |
2008-619
CALGB 10501: A Phase III Intergroup CLL Study of Asymptomatic Patients with Chronic Lymphocytic Leukemia Patients Randomized to Early Intervention versus Observation with Later Treatment in the High Risk Genetic Subset with IGVh Unmutated Disease more details
Protocol
Consent Form
|
|
| |
2009-026
Phase III Randomized,Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High Dose Cytarabine)Chemotherapy+Midostaurin or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia
more details
Protocol
Consent Form
|
|
| |
2009-025
SWOG S0521: A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III more details
Protocol
Consent Form
|
|
| |
2008-584
CALGB 10502: Dose Escalation and Phase II Study of Bortezomib (IND #58443, NSC #681239) Added to Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myelois Leukemia Age 60-75 Years more details
Protocol
Consent Form
|
|
| |